

From: Kyle Greenwood <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 6/28/2016 11:17:24 AM
Subject: Funding New Antibiotics – Clinical Progress made through Government Incentives

Building on 18 Years of Sell-Out Success in Europe, SMi is Proud to Present:

Superbugs & Superdrugs USA

November 14th & 15th 2016 | Renaissance Woodbridge Hotel, Iselin, New Jersey

**** REGISTER BY JULY 15TH TO SAVE \$400 ****

[Book here](#) | [Website](#)

IN THE NEWS:

Clinical progress on antibiotics made through US Government financial incentives scheme

EVENT HIGHLIGHT:

Hear more from the US federal agency BARDA, in a keynote address by the Branch Chief of Antibacterials

Dear Mr Tony Kester,

The **\$400 early bird saving** to attend SMi's conference "**Superbugs & Superdrugs USA**" will be ending soon. For further details or to secure your place, visit the website today at www.superbugs-usa.com or contact +44 (0)20 7827 6093.

INDUSTRY NEWS:

Following on from President Barack Obama's 2014 initiative to combat drug-resistant bacteria, which is responsible for an estimated **23,000 deaths a year in the U.S**, the Biomedical Advanced Research and Development Authority (BARDA) announced in recent weeks that federal government financial incentives to drug companies have **helped lead to at least seven late-stage antibiotics** that may fight bacteria prone to turning into dangerous "superbugs".

"We have built a robust portfolio of broad-spectrum antibiotics that possess activity" against such microbes, said Richard J. Hatchett, acting director BARDA*

SPEAKERS INCLUDE:

Dr Christopher Houchens,
Branch Chief, Antibacterials
Program,
BARDA

Dr Rosemarie Aurigemma,
Chief, Biodefense
Drug Development Section,
DMID, NIAID, NIH

Dr Anthony Simon Lynch,
Senior Scientific Director,
Janssen

Dr Alita Miller,
Director of Biology,
Entasis Therapeutics

William J Weiss, Director,
Pre-Clinical Services,
UNT Health Science Center

Dr Domingo Gargallo-Viola,
Co-Founder and CSO,
ABAC Therapeutics

Dr David Cook,
Chief Scientific Officer,
Blueberry Therapeutics

HEAR MORE:

Hear more from BARDA this autumn when **Superbugs & Superdrugs USA** arrives to Iselin, New Jersey on November 14th & 15th. With a focus on the end-to-end support of antibacterial product development, **Dr Christopher Hutchens**, Branch Chief of **BARDA's** Antimicrobials Program, will discuss:

- Launching the biopharmaceutical accelerator to repopulate the antimicrobial pipeline
- Utilizing innovative public-private partnering mechanisms to stimulate clinical product development
- Expanding the BARDA portfolio to include non traditional antimicrobials
- BARDA's efforts to address objectives in the US National Action Plan for CARB

Visit the [website](#) for further details.

REASONS TO ATTEND:

- **Network** with industry-leading experts on drug and antimicrobial material developments
- Learn new **funding opportunities** from BARDA and NIH to combat antimicrobial resistance
- **Strengthen your antibiotic pipeline** with new insights on microbiome profiling to fight multi-resistant gram negative infections
- Hear important discussions on **tackling major bottlenecks** that hinder development of new antimicrobial drugs with our star panel line-up
- Discover **novel protein-based biologics** for the treatment and prevention of serious bacterial infections from Janssen

GET INVOLVED:

1. Register early and **save \$400** at www.superbugs-usa.com
2. For tailored sponsorship and exhibitor packages, contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
3. For delegate enquiries Matthew Apps on +44 (0)20 7827 6093 or email mapps@smi-online.co.uk

www.superbugs-usa.com

* Source: <http://www.wsj.com/articles/new-drugs-in-testing-to-combat-superbugs-1465947655>

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>